# US 7,608,693 B2 · High affinity human antibodies to human IL-4 receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,693 B2
- Document ID: US7608693B2
- Status: Granted
- Kind: B2
- Application number: 12/260,307
- Filed: 2008-10-29
- Published: 2009-03-19
- Granted: 2009-10-27
- Earliest claimed: 2006-10-02
- Assignees: Regeneron Pharmaceuticals, Inc.
- Inventors: Joel H. Martin; Tammy T. Huang; Jeanette L. Fairhurst; Nicholas J. Papadopoulos
- Web page: https://patentgrep.com/patent/US7608693B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with high affinity (KD), capable of blocking hIL-4 and hIL-13 activity.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment thereof, which specifically binds human interleukin-4 receptor (hIL-4R) comprising the amino acid sequence of SEQ ID NO: 274, comprising a heavy chain variable region comprising three heavy-chain CDRs, and a light chain variable region comprising three light-chain CDRs, wherein said three heavy-chain CDRs comprise the CDR1, CDR2 and CDR3 from SEQ ID NO:162, and said three light-chain CDRs comprise the CDR1, CDR2 and CDR3 from SEQ ID NO:164.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein said heavy chain CDR1 comprises SEQ ID NO:148, said heavy chain CDR2 comprises SEQ ID NO:150, said heavy chain CDR3 comprises SEQ ID NO:152, said light chain CDR1 comprises SEQ ID NO:156, said light chain CDR2 comprises SEQ ID NO:158, and said light chain CDR3 comprises SEQ ID NO:160.

### Claim 3 (depends on 2)

The antibody or antigen-binding fragment of claim 2, wherein said heavy chain variable region comprises SEQ ID NO:162.

### Claim 4 (depends on 2)

The antibody or antigen-binding fragment of claim 2, wherein said light chain variable region comprises SEQ ID NO:164.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein said heavy chain CDR1 comprises SEQ ID NO:148, said heavy chain CDR2 comprises SEQ ID NO:150, said heavy chain CDR3 comprises SEQ ID NO:152, said light chain CDR1 comprises SEQ ID NO:156, said light chain CDR2 comprises SEQ ID NO:158, and said light chain CDR3 comprises SEQ ID NO:160.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein said heavy chain variable region comprises SEQ ID NO:162.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein said light chain variable region comprises SEQ ID NO:164.

### Claim 9

An antibody or antigen-binding fragment thereof, which specifically binds human interleukin-4 receptor (hIL-4R) comprising the amino acid sequence of SEQ ID NO: 274, comprising a heavy chain variable region comprising SEQ ID NO:162 and a light variable region comprising SEQ ID NO:164.

### Claim 10 (depends on 9)

A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 9 and a pharmaceutically acceptable carrier.